Email this article Correlation between Serum Level Magnesium and Non-alcoholic Fatty Liver Disease
Abstract
Background:
Non-alcoholic fatty liver disease (NAFLD) was one of prevalent problems in general population. It was the most common cause of abnormal liver function tests and may lead to steatohepatitis and cirrhosis. The role of many factors has been known in NAFLD. In this study, we investigated the correlation of serum magnesium level and NAFLD after minimizing the role of major confounding factors.
Materials and Methods:
This was a cross-sectional study in the referral patients to the internal medicine clinic. We grouped study patients in two; patients with and without NAFLD. Then, serum level of magnesium was measured, and its relation was studied between both groups.
Results:
Within patients enrolled into study, 55 had NAFLD, and 33 were without NAFLD. Both groups were matched for main confounding factors, including: gender, diabetes and metabolic syndrome (p>0.05). Mean serum magnesium level was 2.26+/-0.35, 2.25+/-0.39 and 2.08+/-0.41 in patients without NAFLD, grade one and two NAFLD, respectively (p=0.06). However it was shown that with each unit increase in serum level of magnesium, risk of fatty liver disease would decrease 50 percent. (OR=0.516, CI=95%,0.147-1.8060.147-1.806 )
Conclusion:
In the current study, we evaluated the relation between serum magnesium level and NAFLD. We showed that patients with a lower serum level of magnesium have 50% more chance to get NAFLD, and it is correlated with higher degrees of fatty liver disease.
CallSend SMSCall from mobileAdd to SkypeYou'll need Skype CreditFree via Skype
Keywords
Full Text:
PDFReferences
- Turecky L, Kupcova V, Szantova M, Uhlikova E, Viktorinova A, CzirfuszA.Serum magnesium levels in patients with alcoholic and non-alcoholic fatty liver.BratislLekListy 2006;107(3):58-61.
- Turecky L, Kupcova V, Szantova M, Uhlikova E, Viktorinova A, CzirfuszA.Serum magnesium levels in patients with alcoholic and non-alcoholic fatty liver.BratislLekListy 2006;107(3):58-61.
- Guerrero-Romero F, Rodríguez-MoránM.Low serum magnesium levels and metabolic syndrome.ActaDiabetol 2002 Dec;39(4):209-13.
- Guerrero-Romero F, Rodríguez-MoránM.Magnesium improves the beta-cell function to compensate variation of insulin sensitivity: double-blind, randomized clinical trial. Eur J Clin Invest 2011 Apr;41(4):405-10.
- Marchesini G, Brizi M, Bianchi G, et al.Nonalcoholic fatty liver disease: a featureof the metabolic syndrome. Diabetes 2001;50:1844-50.
- Tarantino G, Saldalamacchia G, Conca P, Arena A. Non-alcoholic fatty liver disease: further expression of the metabolic syndrome. J GastroenterolHepatol 2007:22293-303.
- Marchesini G, Marzocchi R, Agostini F, Bugianesi E. Nonalcoholic fatty liver disease and the metabolic syndrome. CurrOpinLipidol 2005;16:421-7.
- Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo ClinProc 1980; 55:434.
- Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol 1989; 20:594.
- Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30:1356.
- Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140:124.
- Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40:1387.
- Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107:1103.
- longo DL., Fauci AS., Kasper DL., Hauser SL., Jameson JL., Loscalzo J., Harrison's Principles of Internal Medicine, McGraw Hill ,2012,18th Edition
- Younossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. ClinGastroenterolHepatol 2011; 9:524.
- Stepanova M, Younossi ZM. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. ClinGastroenterolHepatol 2012; 10:646.
- Kotronen A, Yki-Jarvinen H. Fatty liver: a novel component of the metabolic syndrome. ArteriosclerThrombVascBiol 2008;28:27-38.
- Guerrero-Romero F, Bermudez-Peña C, Rodríguez-MoránM.Severe hypomagnesemia and low-grade inflammation in metabolic syndrome.Magnes Res. 2011 Jun;24(2):45-53.
- WeglickiWB.Hypomagnesemia and inflammation: clinical and basic aspects.Annu Rev Nutr. 2012 Aug 21;32:55-71.
- Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population based cohort study. Gastroenterology 2005;129:113-21.
- Sung KC, Ryan MC, Wilson AM. The severity of nonalcoholic fatty liver disease is associated with increased cardiovascular risk in a large cohort of non-obeseAsian subjects. Atherosclerosis 2009;203:581-6.
- Friis-Liby I, Aldenborg F, Jerlstad P, RundstromK, Bjornsson E. High prevalence of metabolic complications in patients with non-alcoholic fatty liver disease. Scand J Gastroenterol 2004;39:864-9.
- Fan JG, Li F, Cai XB, Peng YD, Ao QH, Gao Y. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. J GastroenterolHepatol 2007;22:1086-91.
- Brea A, PuzoJ.Non-alcoholic fatty liver disease and cardiovascular risk.Int J Cardiol. 2012 Nov 8.
- Kanbay M, Yilmaz MI, Apetrii M, Saglam M, Yaman H, Unal HU et al. Relationship between Serum Magnesium Levels and Cardiovascular Events in Chronic Kidney Disease Patients.Am J Nephrol. 2012;36(3):228-37.
- Kupetsky-Rincon EA, UittoJ.Magnesium: Novel Applications in Cardiovascular Disease - A Review of the Literature.AnnNutrMetab. 2012 Aug 14;61(2):102-110.
Copyright (c)